Potentials of Brentuximab Vedotin in the Treatment of Relapse/Refractory Cutaneous T-Cell Lymphomas: Literature Review and Authors’ Observation

Vestnik dermatologii i venerologii
doi 10.25208/0042-4609-2019-95-2-42-49
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov

Related search

Successful Outcomes of Brentuximab Vedotin Therapy in Recurrent/Refractory Cutaneous T-Cell Lymphomas: Two Case Reports

Immunopathology, Allergology, Infectology
2018English

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma

Bőrgyógyászati és Venerológiai Szemle
2019English

Brentuximab Vedotin for Treatment of Non-Hodgkin Lymphomas: A Systematic Review

Critical Reviews in Oncology/Hematology
GerontologyGeriatricsHematologyOncology
2017English

A Phase Ii Trial of Brentuximab Vedotin (Bv) and Lenalidomide (Len) in Relapsed and Refractory (R/R) Cutaneous (Ctcl) and Peripheral (Ptcl) T-Cell Lymphomas: Preliminary Results of a Phase Ii Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2019English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Primary Cutaneous Acral CD8+ T-Cell Lymphomas Relapse More Frequently in Younger Patients

British Journal of Haematology
Hematology
2018English

Pegylated Liposomal Doxorubicin in the Treatment of Primary Cutaneous T-Cell Lymphomas

Haematologica
Hematology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy